Adaptimmune Therapeutics (ADAP) Competitors $0.32 +0.02 (+6.20%) Closing price 04:00 PM EasternExtended Trading$0.33 +0.01 (+1.88%) As of 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADAP vs. SEPN, CADL, DSGN, AVIR, ZYBT, CRVS, MBX, IMMP, PRME, and SLRNShould you be buying Adaptimmune Therapeutics stock or one of its competitors? The main competitors of Adaptimmune Therapeutics include Septerna (SEPN), Candel Therapeutics (CADL), Design Therapeutics (DSGN), Atea Pharmaceuticals (AVIR), Zhengye Biotechnology (ZYBT), Corvus Pharmaceuticals (CRVS), MBX Biosciences (MBX), Immutep (IMMP), Prime Medicine (PRME), and Acelyrin (SLRN). These companies are all part of the "pharmaceutical products" industry. Adaptimmune Therapeutics vs. Septerna Candel Therapeutics Design Therapeutics Atea Pharmaceuticals Zhengye Biotechnology Corvus Pharmaceuticals MBX Biosciences Immutep Prime Medicine Acelyrin Septerna (NASDAQ:SEPN) and Adaptimmune Therapeutics (NASDAQ:ADAP) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership, community ranking and dividends. Does the MarketBeat Community believe in SEPN or ADAP? Adaptimmune Therapeutics received 318 more outperform votes than Septerna when rated by MarketBeat users. However, 71.43% of users gave Septerna an outperform vote while only 63.33% of users gave Adaptimmune Therapeutics an outperform vote. CompanyUnderperformOutperformSepternaOutperform Votes571.43% Underperform Votes228.57% Adaptimmune TherapeuticsOutperform Votes32363.33% Underperform Votes18736.67% Which has stronger earnings & valuation, SEPN or ADAP? Septerna has higher earnings, but lower revenue than Adaptimmune Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSepterna$981K262.53N/AN/AN/AAdaptimmune Therapeutics$178.03M0.47-$113.87M-$0.27-1.20 Do analysts rate SEPN or ADAP? Septerna currently has a consensus price target of $33.00, indicating a potential upside of 468.97%. Adaptimmune Therapeutics has a consensus price target of $1.83, indicating a potential upside of 464.99%. Given Septerna's higher probable upside, analysts clearly believe Septerna is more favorable than Adaptimmune Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Septerna 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Adaptimmune Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Does the media favor SEPN or ADAP? In the previous week, Adaptimmune Therapeutics had 6 more articles in the media than Septerna. MarketBeat recorded 18 mentions for Adaptimmune Therapeutics and 12 mentions for Septerna. Adaptimmune Therapeutics' average media sentiment score of 0.42 beat Septerna's score of 0.38 indicating that Adaptimmune Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Septerna 1 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Adaptimmune Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders hold more shares of SEPN or ADAP? 31.4% of Adaptimmune Therapeutics shares are held by institutional investors. 12.4% of Adaptimmune Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is SEPN or ADAP more profitable? Septerna has a net margin of 0.00% compared to Adaptimmune Therapeutics' net margin of -25.43%. Septerna's return on equity of 0.00% beat Adaptimmune Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets SepternaN/A N/A N/A Adaptimmune Therapeutics -25.43%-74.15%-15.09% SummaryAdaptimmune Therapeutics beats Septerna on 8 of the 14 factors compared between the two stocks. Remove Ads Get Adaptimmune Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADAP vs. The Competition Export to ExcelMetricAdaptimmune TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$83.32M$2.97B$5.54B$7.49BDividend YieldN/A1.53%4.86%4.04%P/E Ratio-1.4730.4323.2518.07Price / Sales0.47383.26361.2686.83Price / CashN/A168.6838.1634.64Price / Book1.913.646.493.99Net Income-$113.87M-$72.06M$3.21B$247.18M7 Day Performance47.23%-10.59%-6.42%-6.42%1 Month Performance-36.58%-16.74%-0.68%-7.44%1 Year Performance-76.53%-30.77%6.05%-4.31% Adaptimmune Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADAPAdaptimmune Therapeutics2.6354 of 5 stars$0.32+6.2%$1.83+465.0%-78.2%$83.32M$178.03M-1.47490Analyst ForecastGap DownHigh Trading VolumeSEPNSepterna2.0409 of 5 stars$6.37+7.6%$34.00+433.8%N/A$282.85M$981,000.000.00N/AEarnings ReportCADLCandel Therapeutics2.2819 of 5 stars$8.66+7.4%$21.00+142.5%+214.2%$281.24M$120,000.00-5.0160Gap DownDSGNDesign Therapeutics1.2647 of 5 stars$4.93+6.0%$8.00+62.3%-2.1%$279.84MN/A-5.8040Gap DownAVIRAtea Pharmaceuticals2.5477 of 5 stars$3.20-0.6%$6.88+115.0%-25.6%$273.68MN/A-1.5570ZYBTZhengye BiotechnologyN/A$5.80+18.9%N/AN/A$273.56M$189.75M0.00278News CoverageGap DownHigh Trading VolumeCRVSCorvus Pharmaceuticals2.2885 of 5 stars$4.25-1.4%$12.38+191.2%+72.6%$273.09MN/A-4.5730MBXMBX Biosciences2.2011 of 5 stars$8.13+3.0%$37.25+358.2%N/A$271.74MN/A0.0036Positive NewsIMMPImmutep1.6886 of 5 stars$1.84-2.1%$8.50+362.0%-34.3%$267.83M$5.14M0.002,021News CoverageGap DownPRMEPrime Medicine2.3133 of 5 stars$2.03+4.1%$13.38+558.9%-71.7%$266.26M$2.98M-0.99234Gap DownSLRNAcelyrin2.9954 of 5 stars$2.64-4.0%$9.60+263.6%-58.1%$265.87MN/A-1.07135Gap Down Remove Ads Related Companies and Tools Related Companies SEPN Alternatives CADL Alternatives DSGN Alternatives AVIR Alternatives ZYBT Alternatives CRVS Alternatives MBX Alternatives IMMP Alternatives PRME Alternatives SLRN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADAP) was last updated on 4/3/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptimmune Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptimmune Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ADAP Stock Free ADAP Stock Alerts